Halozyme, Inc.’s Post

View organization page for Halozyme, Inc., graphic

19,093 followers

Our partner argenx announced FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The treatment is co-formulated with Halozyme's drug delivery technology. We are so proud of the work we are doing with our partners to create improved treatment options that provide meaningful benefits for patients and healthcare providers. https://ow.ly/tTK050SoxMB #Halozyme #subcutaneous #CIDP

  • No alternative text description for this image
Kathy Perez

Head, Global Patient Advocacy and Policy at argenx

3mo

The CIDP Patient Community is excited to have an innovative Treatment Option to consider !! Many thanks to the diligent work of the Halozyme Team to make this possible!

Yogesh Tagad

Global Business Development Manager @ Devsynthesis India Pvt. Ltd. | Small Molecules | Discovery Chemistry| Process development

3mo

Congratulations on this significant achievement! It's truly inspiring to see the collaborative efforts of Halozyme, Inc. and argenx leading to the development of a new treatment for CIDP.

Like
Reply
Linda Sierra

Biotech/Life Sciences Executive Search, DE&I, Latina Executive. SVP, BD & Co-Chair DE&I

3mo

Congratulations Helen, Amy and entire Halozyme, Inc. Team!

Roger Davy

Managing Director at CREO Consulting

3mo

Congratulations! Great to see.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics